Fostamatinib Skates Through OSKIRA-1 With Mixed Results
This article was originally published in Pharmaceutical Approvals Monthly
AstraZeneca/Rigel’s oral SYK inhibitor fostamatinib met a key primary endpoint in the first of three rheumatoid arthritis Phase III studies, but missed another. Investors and analysts are underwhelmed with the efficacy results, although President and COO Raul Rodriguez advises holding on for the other Phase III trials before passing judgment.
You may also be interested in...
Dependent on revenues from AstraZeneca-partnered fostamatinib to fund its growth, Rigel has built a diverse and innovative portfolio. But disappointing results from a Phase IIb dose-ranging trial of fostamatinib – three other pivotal trials will report out soon – could signal trouble for the biopharma. Rigel execs Jim Gower and Raul Rodriguez share perspectives on the AstraZeneca deal and fostamatinib’s prospects.
Pfizer’s newly approved oral RA therapy Xeljanz has an oral advantage over established immune modulators, which all are delivered by needle, but safety questions may slow its adoption.
Facing a raft of patent expiries, AstraZeneca pays richly for Rigel's Phase II oral RA candidate.